Compare AbbVie Inc (ABBV) vs Global X SuperDividend ETF (SDIV) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

SDIV trades at $24.81, up 1.02% with a neutral technical signal. The ETF maintains a consistent dividend payout of $0.18 monthly, providing a high yield for income-focused investors. Recent news highlights SDIV's role in diversification away from AI-heavy portfolios, with Seeking Alpha upgrading it to a buy rating citing attractive valuation and 9.29% yield. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.

SDIV offers exposure to global high-dividend stocks with minimal tech exposure, appealing during market volatility. Key risks include concentration in financials and energy sectors, interest rate sensitivity, and geopolitical factors affecting dividend sustainability. The fund's 6% yield target provides income stability but requires monitoring of underlying holdings' financial health.